Logo

Aushon Biosystems

Quanterix Acquires Aushon With Eye Toward Improved Multiplexing, Point-of-Care Tech
Premium

Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.

Aushon Moves Into Ultra-Sensitive Immunoassay Space With Launch of New Line
Premium

The company has developed a series of cytokine immunoassays for its Ciraplex platform that it said can achieve sensitivity in the femtogram per ml range.

Aushon Biosystems Expands IP Portfolio ahead of Planned Cira Multiplex Platform Upgrade
Premium

NEW YORK (GenomeWeb) – Aushon Biosystems has been building up its IP portfolio ahead of a planned expansion to its Cira immunoassay platform.

IP Roundup: Aushon Biosystems, U of California, Agilent, Affymetrix, Philips, and Ajjer
Premium

Title: Method of and system for applying blocking material to assay substrates. Patent Number: 8,685,486 Filed: Aug. 10, 2011

People in the News: PNNL, Aushon, and More
Premium

Richard Smith, director of proteomics at Pacific Northwest National Laboratory, has been named recipient of the 2013 Award for a Distinguished Contribution in Mass Spectrometry by the American Society for Mass Spectrometry.
Apr 23, 2013

People in the News: Charles Dadswell, Christian Cabou, Susan Vogt, Martin Verhoef, Robert Schueren, and Others
Premium

Mar 1, 2013

People In The News: Mar 1, 2013

Mar 1, 2013

People in the News: Agilent Names DePinho Thought Leader and More
Premium

Nov 1, 2012

AH Diagnostics Distributing Aushon BioSystems Products in Scandinavia

Oct 19, 2012

People in the News: BG Medicine, Caprotec, and More
Premium

Sep 11, 2012

People in the News: Paul Bianchi, Peter Rigby, Jorge Reis-Filho, Martin Bobrow, Chris Holmes, Martin Verhoef, Peter Honkanen
Premium

Sep 7, 2012

People in the News: A New CEO at Aushon
Premium

Aug 21, 2012

IP Roundup: Aushon Biosystems, Sony, Fluidigm, Eppendorf Array Technology
Premium

Jun 29, 2012

New Products: Aushon Biosystems and More
Premium

May 22, 2012

Aushon Biosystems Readies Next-Gen Protein Array System for Launch
Premium

May 17, 2012

New Products: Multiplex Immunoassays from Aushon; Software from Sage-N; and More
Premium

Apr 6, 2012

MD Anderson-Led Team IDs Proteins Linked to HR-Positive Breast Cancer Prognosis
Premium

Feb 10, 2012

Aushon Inks Distribution Agreement with Thermo Fisher
Premium

Nov 11, 2011

Texas Universities Adding 10-Plus New Mass Spectrometers with $10.4M in CPRIT Funding
Premium

Aug 2, 2011

MD Anderson Cancer Center Acquires Aushon Printer for Reverse Phase Protein Array Production
Premium

Apr 8, 2011

New Products: Apr 8, 2011
Premium

Feb 15, 2011

Arrayjet Moves beyond Instrument Market with Launch of Custom Array Services
Premium

Feb 11, 2011

Aushon Inks Deal with Peking University to ID Protein Biomarkers for Colorectal Cancer
Premium

Feb 8, 2011

Aushon BioSystems, Peking University Cancer Hospital to Collaborate on Colorectal Cancer Diagnostics
Premium

Feb 8, 2011

Aushon Enters Predictive Dx Deal with Peking University

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.